And Mr. Paul Burroughs, Director of Communications, you may begin your conference.

Good morning, and welcome, everyone. With me today are David Dodd, the Chairman and CEO; Dennis Turpin, Chief Financial Officer; Richard Sachse, Chief Scientific and Chief Medical Officer; and Jude Dinges, Chief Commercial Officer.

Please take note that during this call, we may be making forward-looking statements regarding future events and the performance of Aeterna Zentaris that involve risks and uncertainties that could cause actual events and results to differ materially. These risks are described in further detail in the company's press releases and reports filed with the U.S.

and Canadian securities regulatory authorities.

These forward-looking statements represent the company's judgment as of today, Friday, May 8, 2015, and the company disclaims any intent or obligation to update these forward-looking statements unless we are required to do so by applicable law or by securities regulatory authority. However, we may choose to update, and if we do so, we will disseminate the updates to the investing public.

It's now my pleasure to introduce the Chairman and CEO of Aeterna Zentaris, David Dodd.

Thank you, Paul. Good morning, everyone.

Thank you for your interest in Aeterna Zentaris and our continued progress in building a successful company.

We have several exciting value development activities to discuss today. Last week, the Data Safety Monitoring Board, following its first interim analysis, recommended that we continue as planned the ZoptEC Phase III trial with our lead oncology compound zoptarelin doxorubicin, a second line treatment for women with advanced, recurrent or metastatic endometrial cancer.

Zoptarelin doxorubicin is an engineered molecule composed of a synthetic peptide carrier linked to the widely used and well-known chemotherapeutic agent doxorubicin. Our product is intended to provide a more impactful delivery of doxorubicin with an improved benefit-risk profile.

In other words, increased survival and lower cardiotoxicity. Conducted under a Special Protocol Assessment from the FDA, the trial's primary endpoint is an improvement in overall survival versus standard doxorubicin.

To date, enrollment for this trial exceeds over 470 patients out of the expected total of 500 patients, and all centers are operational. At this rate, we expect to complete patient recruitment ahead of our projected timeline.

We now expect to complete recruitment in the first half of this year. A second interim analysis at 192 events is planned by year end, with completion of the trial expected by the end of 2016.

Looking forward, we are continuing to develop our commercial plans for zoptarelin doxorubicin and on establishing additional partnerships in strategic territories for the remainder of the world.

As a reminder, our CRO, Ergomed, is paying 30% of the out-of-pocket clinical and regulatory costs up to $10 million.

As you may recall, endometrial cancer is a very important unmet medical need with a large market opportunity. It represents the most common gynecological malignancy.

Approximately 55,000 new cases are expected in the United States this year, with approximately 9,000 patients annually in our target indication.

We estimate that the potential annual market opportunity in the U.S. alone represents between $300 million and $400 million in treating advanced recurrent endometrial cancer.

And considering additional potential indications, our product has an annual market opportunity of approximately $1 billion in the United States.

Zoptarelin doxorubicin is potentially the first FDA-approved medical therapy for recurrent endometrial cancer. We believe this could result in its rapid adoption as the core therapy for patient treatment and management.

Still with zoptarelin doxorubicin, a few weeks ago, we announced the filing of an application for a patent on a novel method of manufacturing this product. The claimed manufacturing process is expected to result in a significant reduction in the cost of goods sold, providing a stronger competitive position for the company.

Because this is a complex molecule, it is expensive to synthesize. The patent application, if granted, is anticipated to make it difficult for generic manufacturers to produce the compound on a financially feasible basis after our composition of matter patent on zoptarelin doxorubicin expires.

With the 2015 expiration date of the U.S. composition of matter patent on the horizon, we saw the means to maintain our advantage for this compound beyond the 5-year period of exclusivity granted to new chemical entities, which we expect to apply to zoptarelin doxorubicin.

The compound could become a very important oncology tool if our Phase III study achieves its endpoints. By reducing the complexity of production and the cost of the compound, we'll have greater flexibility in potentially ensuring that patients on a worldwide basis have access and can benefit from this therapy.

As for Macrilen, we recently announced our plans to conduct a new confirmatory Phase III clinical study to demonstrate the efficacy of Macrilen, our novel patented orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency, otherwise known as AGHD, as well as conducting a dedicated thorough QT study to evaluate the effect of Macrilen on myocardial repolarization.

This decision followed a positive and successful end-of-review meeting with the FDA regarding our new drug application for Macrilen. We had requested the meeting to gain clarity on the approval deficiencies described in the Complete Response Letter we had received on November 6 of last year.

And our decision was also based on advice from a panel of U.S. and European endocrinology experts, who voiced to stress their confidence in Macrilen’s efficacy and on the fact that there currently is no FDA-approved diagnostic test for AGHD.

The confirmatory Phase III study will be conducted as a 2-way crossover, with the insulin tolerance test as the benchmark comparator. The study population will consist of patients with a medical history documenting risk factors for AGHD and will include a spectrum of patients from those with a low risk of having AGHD to those with a high risk of having the condition.

We expect to initiate the trial by year end.

We also plan to conduct a Phase III study that will satisfy the registration requirements of the European Medicines Agency or EMA, as well as the FDA. Following our recent successful EMA science advice meeting, we expect to proceed with the study design very soon.

We continue to believe that Macrilen represents a strong value proposition. It could become the only FDA-approved product for evaluating AGHD.

It is accurate, comparable to the standard current methods. It is safe and well-tolerated.

It is very convenient versus the insulin tolerance test. As you recall, it's an oral versus IV or IM injections.

It is simple, a single blood draw is possible, has shorter follow up, and certainly, involves less medical supervision.

In addition to our development programs, during this quarter, we transferred our discovery library of approximately 100,000 unique compounds to the South Carolina Center for Therapeutic Discovery and Development, which is part of The Medical University of South Carolina or MUSC. This agreement will therefore make it possible to continue drug discovery activities without the cost and risk that they imply.

The Center has agreed to conduct screening and preclinical activities, with a view towards submitting to us at least one development candidate per year during a 10-year period beginning in 2018. We will receive the right of first refusal to license the development candidates.

Should we decide to further develop a development candidate submitted by the Center, MUSC will license the compound candidate to us and be entitled to a royalty on the net sales of all commercialized products developed from the development candidate. However, should we decide to not further develop a development candidate submitted by the Center, MUSC will pay us a royalty on net sales of all commercialized products developed from the development candidate.

Relative to our commercial operations. During the quarter, we ramped up selling efforts related to our co-promotion agreement with ASCEND Therapeutics, which we entered into in August of 2014.

Pursuant to that agreement, we are co-promoting ASCEND's product, EstroGel, a leading non-patch transdermal hormone replacement therapy product, in specific agreed-upon U.S. territories in exchange for sales commission as based upon incremental sales volume of EstroGel that are generated over preestablished baselines.

Detailing efforts associated with EstroGel commenced in earnest early in the first quarter of 2015, following the completion of sales force training and other knowledgeable transfer activities that had been underway since late last year. During the quarter, our 19 sales representatives initiated calling on prescribing physicians in their respective territories, and overall feedback from the field has been positive.

Subsequent to quarter end, we began exceeding preestablished unit sales baseline thresholds on a total nation basis, as discussed later.

EstroGel is the leading non-patch transdermal brand of estrogen replacement therapy commercialized in the U.S. It is marketed in over 70 countries and is the most prescribed estrogen product in Europe, as well as the most prescribed transdermal product -- estrogen product, rather, in Canada.

EstroGel represents an exciting market opportunity for our company. In 2013, the market for estrogen replacement therapy was estimated at $3.6 billion in annual sales in the U.S., with the non-patch transdermal products, which is where we compete, representing the fastest-growing segment, generating approximately $100 million in annual sales.

Our focus on EstroGel is to grow and differentiate that brand, achieving a leading category position in every territory we occupy. Our initial information indicates that within the AEZS territories, we are achieving growth rates significantly above the overall market and category performance.

As for our overall commercial activities, we are actively seeking opportunities to expand our commercial portfolio through successful in-licensing, acquisition or promotion of already commercialized products, with a focus in endocrinology, oncology and women's health.

Just yesterday, we announced the signing of an agreement with EMD Serono, resulting in our upcoming launch of the promotion of Saizen, a recombinant human growth hormone indicated for the treatment of growth hormone deficiency in children and adults.

In the U.S., along with our partner collaborator, ASCEND Therapeutics, we will detail Saizen to designated medical professionals, significantly increasing the share of voice of this product in its market. In return for achieving new patient starts above an agreed upon baseline, we will receive compensation.

As part of this effort, we have subcontracted with ASCEND Therapeutics, resulting now in 53 incremental sales reps that will significantly increase the field promotion behind Saizen.

Saizen competes in a market of almost $2 billion in the U.S., which is growing at a double-digit rate. Annually, approximately 40,000 pediatric patients are treated with growth hormone.

Saizen is indicated for the treatment of growth hormone deficiency in both children and adults. Currently, Saizen is the only product available that offers a needle-free delivery system.

In addition, patients receive 24/7 nursing support for the device training and a dedicated case manager to assist in resolving access and reimbursement issues.

Our focus is to rapidly train our representatives in order to launch selling of Saizen during the current quarter. We look forward to the launch of the commercial activity and to updating you as we strengthen the share of voice and subsequent market share increases of Saizen.

Finally, we continue our effort to streamline R&D activities, increase commercial operations capability and our overall flexibility. This initiative has resulted in the reduction of 31 staff, mainly affecting drug discovery and preclinical stage programs.

Today, we are more sharply focused, with greater flexibility and ability to drive towards our goal of becoming a growth-oriented competitor actively developing customers, while ensuring that we have a vibrant active portfolio of future growth products.

EstroGel, achieving continued and increased success in market share growth; Saizen, successfully launching our selling and market share development; adding registered products to our commercial portfolio; the ZoptEC Phase III trial, to complete patient recruitment by midyear and achieve second interim analysis by year end and to continue our commercial launch preparation; Macrilen, to complete the necessary activities to successfully initiate our confirmatory trial before year end; and to complete our global resource optimization program.

Finally, in March, we announced the completion of a public offering that further strengthens our balance sheet to position us well towards successfully executing these programs that we believe are critical in building Aeterna Zentaris.

I will now turn the call over to our Chief Financial Officer, Dennis Turpin, for meet -- more details on this and other financial activities. Dennis?

Thank you, David. First, let me update you on our cash position.

Our cash and cash equivalents totaled $53.3 million as of March 31, 2015. This is compared to $34.9 million as of December 31, 2014.

This balance includes our most recent public offering of 59.7 million units, which generated net proceeds of approximately $34.4 million.

We now have the necessary funding to continue to advance our strategic initiatives, more particularly the ongoing Phase III ZoptEC trial, the Macrilen expected initiation of a confirmatory Phase III trial, as well as our business development and commercial opportunities.

Regarding our burn rate, our operating burn rate for the first quarter of 2015 was approximately $10.2 million, an average of $3.4 million per month. Taking into account our already mentioned strategic initiatives, we continue to expect that our overall operating burn in 2015 will range from $33 million to $35 million.

Now more details about our results for the quarter ended March 31, 2015. Our net R&D costs were $4.5 million for the quarter ended March 31, 2015, compared to $5.8 million for the same period in 2014.

The decrease for the 3-month period, as compared to the same period in '14, is attributable to lower comparative employee compensation and benefits costs, facilities rent and maintenance, as well as other costs.

SG&A costs were $5.1 million for the quarter ended March 31, 2015, compared to $2.4 million for the same period in 2014. The quarter-over-quarter increase is attributable to our increased selling activities associated with the co-promotion efforts related to EstroGel.

Additionally, approximately $800,000 of the quarter-over-quarter increase is attributable to transaction costs incurred in connection with the completion of our most recent financing and associated to our warrant.

Net loss for the quarter ended March 31, 2015 was $9.7 million, compared to $4.4 million for the same period in 2014. The increase in net loss for the 3-month period ended March 31, 2015, as compared to the same period last year, is due largely to higher competitive SG&A expenses and to higher comparative net finance costs, partially offset by lower comparative R&D cost.

Well, thank you for your attention. Now here's David.

Thank you, and at this time, we will entertain questions that you may have.

It's actually Dr. Mccarthy for Jason Kolbert today.

I have 2 questions. But first, it sounds like everything is going really well.

We're excited about the size and deal that you just announced yesterday.

So first, in terms of size and promotion, beyond adding revenues to the bottom line for Aeterna Zentaris, and since it's a growth hormone for growth hormone deficiency, is there an opportunity to kind of co-promote Macrilen's progress to the med -- and kind of reinvigorate the medical community about potential diagnostic and Macrilen coming -- going back into Phase III? Could you comment on that?

Well, you're -- Jason, this is David Dodd. You're absolutely correct.

There has been a real interest in seeing Macrilen come to the market within the endocrinology community. And so this provides us an opportunity, certainly once it's an approved product, to do the obvious, which is combine promotion of both of them to the target audiences.

But at the same time, certainly it will enable us to maintain a high level of awareness of the product and where it is in active development. And as you may recall, the development program, as we've said, we anticipate would be no more than 18 months and possibly 12 to 15 months for the clinical program.

So it's not like a long-term challenge to keep awareness up, but at the same time, it will be very beneficial. And yes, it will also begin to brand us in the area of endocrinology, which is very important to us.

Great. That sounds great.

So can you also just discuss the changes in the manufacturing, I know you filed the patent in Europe for zoptarelin doxorubicin, and really what the percent change in cost of goods could potentially be relative to where they are now?

Yes, we have communicated in recent presentations that it will reduce those costs in excess of 50%.

Wow, so that's great.

It's a significant, to say the least, significant improvement on not only the cost structure for us, but also the competitive positioning relative to generic, which will not be able to utilize this method, and will have a much higher cost structure.

Congratulations on the Serono deal. And it is really commendable that over the last 3 quarters, you have been able to get 2 commercial products in the endocrinology business to establish the commercial structure that you were talking of when I first met you about 9 months ago.

So at this point, and now that you have 2 things on your hand, are you trying to take a breather, let this product establish themselves before going back to the market and looking for more? Or do you want to continue building this portfolio?

Yes, our -- we have a major -- we're not a large company, as you know, and we restructured and all, but we have individual, certainly within Jude's organization and within our colleague's organization, that's ASCEND and now EMD Serono, and collectively and respectively, they are maintaining and heightening the focus on the commercialization of both EstroGel and Saizen, so that, if anything, increases.

Simultaneously, we are increasing our efforts to look for commercial products, with the goal being to acquire or in-license products in which we would begin to book sales. And there, as you may know, we discussed where we have a small internal team working in business development, and we have 2 very capable, highly experienced, well-networked individuals working with us in this area from the outside, and we all work together as one team.

It's a major activity of my own.

So if anything, we now are raising our activity, because we have seen that as we have entered the commercial realm, the types of opportunities tend to start coming to us earlier and more proactively, because people are recognizing not only what we'd like to do, but that we're actually doing it, and we now have the basis of being able to commercialize products very effectively and all. And so it results in having increased opportunities put into your plate.

So we have active projects right now that could potentially result in the actual acquisition of assets for which we'd be booking sales, managing the supply chain process, the -- leading the efforts behind access reimbursement, et cetera, and that's all part of the plan that we expressed starting almost 2 years ago. And it was one step at a time, we stay focused on it.

But we keep everybody updated. So it's very important to us at each of these quarterly things to tell you exactly what we're doing relative to what we have told you in the past we intend to do.

And we check them off, and that's what we're focused on.

So we have not slowed down. We've actually secured financing commitments, significant financing commitments from some outstanding financing firms that want to work with us on bringing in assets, so we're much better prepared now and focused, and hope to be making further announcements yet this year.

Yes, and nothing succeeds like success, as they say. But looking again into the Serono deal a little bit closer, how do you see the Saizen business growing for you?

And when we think about this particular collaboration, is this quite similar to what you started off with ASCEND? And again, in terms of payment scheme and payouts, what do you need to pay out to ASCEND, not only for using their persons in your territories, but also in ASCEND's territories?

How does -- how does all that kind of work out?

Good question. And so I'll break them down and answer them.

In the sense of earning a commission, it's similar. We will be measured and we will be focused on, very specifically, adding incremental new patient starts.

In this marketplace, the -- every company focuses on a new patient start. They have processes in -- every company has processes and procedures in place, EMD Serono has outstanding, as I mentioned some of them today, to work with the patients, to work with the parents, certainly, of pediatric patients, to ensure they know their reimbursement pathway, et cetera, available to them and all the options they may have.

If they have questions on how to use the device, there is 24/7 access, as I mentioned also. All of that will continue and all.

We will be focused in our 53 territories with specific targets that we have worked together on preparing, looking at the opportunity, which is significant in this marketplace and all, and then we will sell, the 53 of those, of which -- I think we have 36% of these incremental reps, meaning 19 out of the 53, are our reps and all. Our -- each territory will be earning a commission rate for that respective company based upon the addition of new patient starts.

And our financing -- our financial structure, which hasn't been in detail disclosed, is such that it's a nice balance. We will receive -- overall, if one looks at what is achieved by this incremental increased activity, we will receive significantly more than the 36%, which would be the 19 over 53 and all, which is related -- which is similar in a sense to how we work on EstroGel on reverse.

But it's related to the fact this is an opportunity that has been led, identified and brought in by Aeterna Zentaris in that way, but working in conjunction to also add additional, not only cash opportunity, but selling opportunity for the ASCEND reps and all.

It's part of what we talked about when we formed the agreement, what we talked about, meaning ourselves and ASCEND, that let's build our respective portfolios, work together here in the U.S. in these areas.

And so this is something that together we evaluate, but it's been led by ourselves. And because of that, the commission, let's say structure, reflects that.

For Saizen, now that you've in-licensed another product, you've got 2 products in the bag, would you consider increasing the size of your sales force detailing that product?

And second question, just in terms of in-licensing your next product or what you're looking at, what are the top 3 criteria that you're looking for, for your next deal?

Okay, there is -- our assessment is there is no -- regarding the size of the sales force, when we look at the number of targets that we cover and our capacity for EstroGel and now with Saizen, and the number of targets that we're targeting, and the field out there in endocrinology and all, there is not a necessity to increase the number of sales reps. We feel very good about our ability to deliver and to -- our capacity of delivering the details.

And so there is not a need to do that. If we felt there was a need, we would probably do that, because we want to make sure we're successful in it.

But there isn't a need based upon that marketplace and all. Approximately, as you may recall, there are about 5,000 endocrinologists out there, which 2,500 is one -- is what one would normally really focus on, and we're focusing on less than that because of the targeting capabilities and the refinement that we have with -- on Saizen with EMD Serono.

Similarly with EstroGel, ASCEND has a very precise targeting methodology and all, which has worked exceedingly well with them, and that's how we structured what we needed. There was nothing magical with 19.

We would have done 25 if we needed 25, and we felt the opportunity was there. And if it was only 15, we probably would have -- probably still done close to 20, but maybe a few less.

So that's how we've established that. Now the -- so I hope that answers that part of the question.

Regarding looking at other opportunities, a couple of criteria as we look at them. Certainly, our preference is in the areas of -- with no particular importance of these 3 areas, but oncology, endocrinology and women's health are the 3 areas in which we are most focused on.

I will say that both with our agreement with MUSC and in other areas, we feel that there is some opportunities within, let's say, neurology/CNS on a select basis that could fit and could be useful for us. So we don't discount those areas, and we evaluate various opportunities in there.

So if one were asking, and I'd -- we'd probably say it's probably more like 3.5 to 4 of those therapeutic areas. So we'd look at that.

We are very interested in booking sales, in managing the process, handling the challenges and the risk of the opportunity through our access reimbursement.

I also want to mention, we -- it's not a license that we have executed with either ASCEND or with EMD Serono. They are promotional services agreement, because they are their products, their NDAs, and they continue to book the sales.

And that's just a -- just a little nomenclature, but just to remind you that what we have is that form of agreement.

But the criteria we're looking at is certainly the fit, which because -- so that means we won't need a lot of representatives. We feel, in general, if we're able to license a gynecologic oncology product or buy such a product, we would probably need no more than 50 sales reps.

So we feel that those are manageable numbers. And in certain areas, if it's a fit with what we're currently doing, we would look at incrementally increasing the coverage of the existing sales organization.

If it's something in another area, we would consider a new vertical sales force, because it would require that, and we're prepared to do that. So we look at the fit.

We look -- we're very focused on something that is more of a license or an acquisition of a product. So we're interested in that.

If it is a legacy or -- we always look at products already on the market. So our evaluation focus is very deeply on what are the levers, the commercial levers that address access reimbursement, differentiation, either real or perceived, in the marketplace, are there ways to be able to place it in the hands of a sales organization and a marketing organization and be able to differentiate it to some extent so we can increase value.

And those -- very straightforward, those are the criteria we look for.

A couple of, I think, quick questions. With regards to the Ergomed agreement, they are paying up to $10 million.

Can you disclose how much they have paid and how much is left? Or is that not to be disclosed?

Just a second. I don't have the exact figures in front of me.

We'll get back to you on that question.

George, I would also say, it's -- I'm not an employee of Ergomed, but we're very pleased with the working relationship with them. They believe in our product.

They stay very close to us on that. And we have no complaints.

And we have been very pleased with the working relationship.

That's terrific, so -- and after -- what is their -- do you have any follow-on once zoptarelin is approved, assuming it's approved? Are they -- what are their -- what are they going to get, if anything?

They will receive a percentage of net income and that is up to a predetermined level. We haven't disclose that.

But it's not of net sales, it's of net income. It's a single-digit percentage.

And that will be reflective of what they invested in, in working with us on the front end.

Okay, great. With regard to the production change and the new patent, is there any regulatory impact with that?

I mean, you're basically -- it sounds like, with a 50% reduction, you're dramatically changing the production process. Do you have to do bioequivalency studies after the Phase III?

What -- is there any regulatory issues there that we need to be concerned about?

We're clarifying that right now, but it is felt very strong that there are none because it is -- all of it is within the process of producing the API [ph]. And as we have examine that, we don't believe there'll be any incremental work that will need to be done, but that will be clarified in the near term.

Okay. That's important, because that one, it's important [indiscernible].

I'm sorry?

You're absolutely right. It's a very important question and one that which we have examined in great detail and will continue, and then we'll reach a confirmation of that.

We're in no debates about it with any regulatory agency. It's just simply we're in preparation for a confirmatory meeting, if you want to call it that.

Okay. And finally, I have a question about the MUSC agreement, 2 questions regarding that.

One is, are there any restrictions at all by the discovery group that you'll see on what indications to look for? Number one.

And number two, what's left in Frankfurt now? Is that basically just clin ops?

Now, well, with the MUSC agreement, we have designated therapeutic areas of interest to us. And so, as I mentioned, in those areas, when they present us, if we go forward with it and we commercialize a product, they would then be -- they would receive a royalty.

If it's something that we aren't interested in and they go forward and another company develops it, we'll receive something back. If it's a compound that is not within our areas, and they develop it and another entity goes forward with it, we would receive a smaller type of royalty, but still something within there.

So it works very well. It's very well balanced and all.

Within Frankfurt, what we have is still our chemical operations, our clinical operations, so basically all elements of R&D, with a significant reduction in drug discovery, because that was where we wanted to transition that to an external entity, which we've successfully done. We also have business development, besides market research, small team there working there, because we're looking for products everywhere.

And their responsibility is not only to look in Europe, which is simply convenient for us, because we can reach out to companies that are based in the EU, and also we have relationships out of that office with companies around the world and all. We manage our relationship with Sinopharm A-Think, which is going very well.

We're in the midst of the technology transfer process there. We had our first steer -- Joint Steering Committee in March, and all of that is managed out of Frankfurt also.

So what we have done there is what we said we were going to do, which is to focus, to tighten up. We've actually increased our clinical development staff there, with addition of clinicians on the team.

So we're going in the direction we have communicated that we intend to go in, and we're delivering on it.

And on a sidenote, do you have reduced space there, and if so, were you able to sublease any space that...?

Yes, it's -- that's almost like a planted question. We have been extremely successful in subleasing to multiple companies.

We have also been very successful in selling equipment that we no longer use in excess of $0.5 million that we've raised, which is equipment that wasn't -- we weren't using and other firms were interested in. So we have optimized the value of resources beyond simply the staffing and all.

And internally, we kid our colleagues in Frankfurt that they're becoming the first profit center.

And for full disclosure, David, that was not a planted question.

No, I know it. We also transferred our NMR out to a university there.

And it's somewhat of an analogous type of an arrangement that we've done with MUSC. And they will be -- that would now be their property, they will work with it.

And in return, we're going to receive certain services for it. So again, it's been a very good process we've gone through.

Just -- and most of the questions, my questions, have been answered. But I just have one follow-up here, I guess, regarding the Phase III endometrial cancer study information flow.

Earlier in the year, you announced that there would be an update during the first half of the year. And I was just wondering if what we saw last week with the Safety Committee information and/or what you've released or talked about this morning constitutes that update or will there be another sort of -- are you planning or expecting another, a news event around that right now?

Unfortunately, and we probably share the same frustration you have, the first interim analysis was scheduled to simply be a futility analysis, and that was the update that we -- that was concluded and communicated last week, on the 27th of April and all. And that included where the Data Safety Monitoring Board examined all data on efficacy and safety regarding it.

But their charge was then to issue a recommendation relative to should we continue -- do they recommend we continue with the program, or would they recommend for whatever reasons that they might expanded on that we not? And they recommended that we do continue and all.

Of course, all of us were wondering what they actually are seeing and all, but we -- that was not scheduled to be part of it.

And so the other updates that might relate to that program, either patents or whatever, just other things we're doing, but the update was the -- that we did get a continuation, which we're excited about.

The other update I would say is that we are tracking so that we expect a full patient enrollment to be completed by the end of the first half, which is ahead of schedule, and that we feel increasingly confident and are anticipating that we will be announcing the second interim results, which would be after 192 events, before year end, and possibly in the early part of fourth quarter rather than the later part.

So those are the best updates we can give you. I wish I knew more.

I wish I could say more to you. But at this point, we just don't have the information, and to protect the integrity of the statistical integrity of the trial, that's why we don't have it.

Thank you. And this -- again, this is David Dodd.

I just want to thank everybody for your interest in Aeterna Zentaris and in our continued development of the company.

And I want to underscore and emphasize that 2 years ago when we all began to know each other and talk about what we are trying to do here, we discussed this is -- a lot of challenges facing this company, a lot of challenges historically and all. But what our focus was, and we continue to deliver step-by-step and we want you to evaluate us, track us and all, is one, build the right team.

We have the right team today. We've restructured, reduced our cost structure.

We've done a lot of sort of things people have talked about and thought about. And also to focus and move forward into the commercial arena.

Is our goal to be a long-term contract sales organization? Absolutely not.

It's to book sales, to deal with it, to be having to report to you what our earnings per share is and whether or not we're going to improve it to the degree you think we should, et cetera, and all of those types of things. And we continue to progress one step at a time.

And at the same time, to deal with challenges that arise.

We had a Complete Response Letter that occurred. We conveyed it immediately.

We met as soon as we could with the FDA. We've come back.

And very rapidly, we're now moving into the realm of trial initiation. We will keep you updated on that.

We will keep you updated on zoptarelin doxorubicin, a product for which we all share great anticipation and excitement, belief in, at this stage. And at the same time, we are just as excited about the building of EstroGel and Saizen in the marketplace.

And we look forward to further updating you on an ongoing basis and answering your questions.

So have a wonderful day. Thank you for your interest.